*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2023 | Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway European journal of medical research · preclinical | PMID 37710348 |
| 2022 | Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation Microvascular research · preclinical | PMID 34856183 |
| 2019 | Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy Die Pharmazie · preclinical | PMID 31526442 |
| 2018 | The Safety and Efficacy of Growth Hormone Secretagogues Sexual medicine reviews · preclinical | PMID 28400207 |
| 2018 | The CD36-PPARγ Pathway in Metabolic Disorders International journal of molecular sciences · preclinical | PMID 29883404 |
| 2015 | Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases Endocrine · preclinical | PMID 25645463 |
| 2014 | The cardiovascular action of hexarelin Journal of geriatric cardiology : JGC · preclinical | PMID 25278975 |
| 2014 | We are ageing BioMed research international · preclinical | PMID 25045704 |
| 2013 | Hexarelin treatment in male ghrelin knockout mice after myocardial infarction Endocrinology · preclinical | PMID 23861368 |
| 2008 | Hexarelin: a multi-receptor peptide Journal of endocrinological investigation · preclinical | PMID 18787392 |
| 2001 | Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death Endocrine · preclinical | PMID 11322493 |
| 1999 | Hexarelin as a test of pituitary reserve in patients with pituitary disease Clinical endocrinology · preclinical | PMID 10469018 |
| 1997 | Interaction of the growth hormone releasing peptide hexarelin with somatostatin Clinical endocrinology · human | PMID 9425393 |
| 1997 | Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function Neuroendocrinology · preclinical | PMID 9067986 |
| 1996 | The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity Clinical endocrinology · human | PMID 8762732 |
Hexarelin (Hexarelin (GHRP; Examorelin)). Synthetic hexapeptide growth-hormone-releasing peptide (GHS-R agonist). Potent GH release; also has CD36-mediated cardioprotective effects studied independently of GH.
Commonly discussed uses: GH-axis research, cardiovascular research interest. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic hexapeptide growth-hormone-releasing peptide (GHS-R agonist). Potent GH release; also has CD36-mediated cardioprotective effects studied independently of GH.
Reported considerations: cortisol/prolactin elevation (more than ipamorelin), desensitisation with continuous use, water retention. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg, typical 100-200mcg 1-2x/day, high 200mcg 3x/day. Administration: subcutaneous. Half-life: ~70 min.
Australian status: Not ARTG-registered; research; WADA prohibited (S2). WADA-prohibited. Not approved for human therapeutic use. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): Hexarelin + GHRH analogue (anecdotal, with desensitisation caveat). Stacking increases interaction/safety uncertainty.